Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.59	$0.37	$0.17 ▼ $3.54	$1.88M	N/A	175,471 shs	10,359 shs
CFRX ContraFect	$0.05	$0.05	$0.04 ▼ $13.02	$535K	0.29	1.39 million shs	910,216 shs
UPC Universe Pharmaceuticals	$3.48 -2.5%	$3.74	$2.51 ▼ $2,100.00	$1.96M	1.43	267,710 shs	3,353 shs
VCNX Vaccinex	$0.52 -3.1%	$0.78	$0.25 ▼ $1.40	$1.34M	1.1	3,044 shs	115 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	+10.49%	+2.86%	+47.46%	+168.06%	-79.30%
CFRX ContraFect	0.00%	0.00%	0.00%	0.00%	0.00%
UPC Universe Pharmaceuticals	+2.19%	-20.57%	+0.43%	-36.45%	-99.82%
VCNX Vaccinex	+26.04%	-14.35%	-47.76%	-21.81%	-89.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXI Avenue Therapeutics	1.665 of 5 stars	0.0	3.0	0.0	4.6	0.6	0.0	1.9
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	0.5169 of 5 stars	0.0	4.0	0.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	N/A	N/A	N/A
CFRX ContraFect	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	($19.92) per share	N/A
UPC Universe Pharmaceuticals	$19.29M	0.10	N/A	N/A	$163.50 per share	0.02
VCNX Vaccinex	$388K	3.46	N/A	N/A	($2.59) per share	-0.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$0.95	0.03	∞	N/A	N/A	-471.57%	-296.50%	N/A
CFRX ContraFect	-$65.15M	-$19.27	N/A	N/A	N/A	N/A	N/A	-138.70%	N/A
UPC Universe Pharmaceuticals	-$6.16M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
CFRX ContraFect	N/A	0.53	0.53
UPC Universe Pharmaceuticals	N/A	N/A	N/A
VCNX Vaccinex	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
CFRX ContraFect	7.85%
UPC Universe Pharmaceuticals	0.18%
VCNX Vaccinex	50.11%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	1.80%
CFRX ContraFect	0.62%
UPC Universe Pharmaceuticals	57.38%
VCNX Vaccinex	51.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.18 million	2.02 million	Not Optionable
CFRX ContraFect	23	10.70 million	10.64 million	Not Optionable
UPC Universe Pharmaceuticals	220	563,000	731,000	Not Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data

CFRX, UPC, ATXI, and VCNX Headlines

Recent News About These Companies

Vaccinex presents promising cancer treatment data at ASCO

May 29, 2025 | uk.investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025

May 29, 2025 | nasdaq.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025 | globenewswire.com

AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finanznachrichten.de

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finance.yahoo.com

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

April 22, 2025 | markets.businessinsider.com

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025

April 21, 2025 | quiverquant.comQ

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025 | globenewswire.com

Vaccinex director resigns, no disagreement cited

March 21, 2025 | investing.com

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

March 10, 2025 | finance.yahoo.com

Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 8, 2025 | finanznachrichten.de

Vaccinex to delist common stock from Nasdaq

March 7, 2025 | markets.businessinsider.com

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025 | globenewswire.com

Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Vaccinex receives delisting notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Shares Tumble 63% On Nasdaq Delisting

December 17, 2024 | marketwatch.com

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

December 17, 2024 | finance.yahoo.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

December 17, 2024 | benzinga.com

Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

December 17, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

Top Headlines

View All

CFRX, UPC, ATXI, and VCNX Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.59 0.00 (0.00%)

As of 03:50 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Universe Pharmaceuticals NYSE:UPC

$3.48 -0.09 (-2.52%)

As of 04:00 PM Eastern

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

Vaccinex NASDAQ:VCNX

$0.52 -0.02 (-3.08%)

As of 01:03 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time